Literature DB >> 30602611

HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Fredrick H Omondi1, Sandali Chandrarathna1, Shariq Mujib2, Chanson J Brumme3, Steven W Jin1, Hanwei Sudderuddin1, Rachel L Miller1, Asa Rahimi1, Oliver Laeyendecker4,5, Phil Bonner2, Feng Yun Yue2, Erika Benko2, Colin M Kovacs2,6, Mark A Brockman1,3,7, Mario Ostrowski8,9, Zabrina L Brumme10,3.   

Abstract

The HIV accessory protein Nef modulates key immune evasion and pathogenic functions, and its encoding gene region exhibits high sequence diversity. Given the recent identification of early HIV-specific adaptive immune responses as novel correlates of HIV reservoir size, we hypothesized that viral factors that facilitate the evasion of such responses-namely, Nef genetic and functional diversity-might also influence reservoir establishment and/or persistence. We isolated baseline plasma HIV RNA-derived nef clones from 30 acute/early-infected individuals who participated in a clinical trial of early combination antiretroviral therapy (cART) (<6 months following infection) and assessed each Nef clone's ability to downregulate CD4 and human leukocyte antigen (HLA) class I in vitro We then explored the relationships between baseline clinical, immunological, and virological characteristics and the HIV reservoir size measured 48 weeks following initiation of suppressive cART (where the reservoir size was quantified in terms of the proviral DNA loads as well as the levels of replication-competent HIV in CD4+ T cells). Maximal within-host Nef-mediated downregulation of HLA, but not CD4, correlated positively with post-cART proviral DNA levels (Spearman's R = 0.61, P = 0.0004) and replication-competent reservoir sizes (Spearman's R = 0.36, P = 0.056) in univariable analyses. Furthermore, the Nef-mediated HLA downregulation function was retained in final multivariable models adjusting for established clinical and immunological correlates of reservoir size. Finally, HIV subtype B-infected persons (n = 25) harbored significantly larger viral reservoirs than non-subtype B-infected persons (2 infected with subtype CRF01_AE and 3 infected with subtype G). Our results highlight a potentially important role of viral factors-in particular, HIV subtype and accessory protein function-in modulating viral reservoir establishment and persistence.IMPORTANCE While combination antiretroviral therapies (cART) have transformed HIV infection into a chronic manageable condition, they do not act upon the latent HIV reservoir and are therefore not curative. As HIV cure or remission should be more readily achievable in individuals with smaller HIV reservoirs, achieving a deeper understanding of the clinical, immunological, and virological determinants of reservoir size is critical to eradication efforts. We performed a post hoc analysis of 30 participants of a clinical trial of early cART who had previously been assessed in detail for their clinical, immunological, and reservoir size characteristics. We observed that the HIV subtype and autologous Nef-mediated HLA downregulation function correlated with the viral reservoir size measured approximately 1 year post-cART initiation. Our findings highlight virological characteristics-both genetic and functional-as possible novel determinants of HIV reservoir establishment and persistence.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CD4 downregulation; HIV reservoir; HIV-1; HLA downregulation; Nef; viral pathogenesis

Mesh:

Substances:

Year:  2019        PMID: 30602611      PMCID: PMC6401425          DOI: 10.1128/JVI.01832-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

Review 1.  Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.

Authors:  Roger J Pomerantz
Journal:  HIV Clin Trials       Date:  2003 Mar-Apr

2.  HIV-1 integration landscape during latent and active infection.

Authors:  Lillian B Cohn; Israel T Silva; Thiago Y Oliveira; Rafael A Rosales; Erica H Parrish; Gerald H Learn; Beatrice H Hahn; Julie L Czartoski; M Juliana McElrath; Clara Lehmann; Florian Klein; Marina Caskey; Bruce D Walker; Janet D Siliciano; Robert F Siliciano; Mila Jankovic; Michel C Nussenzweig
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

3.  Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.

Authors:  Pontiano Kaleebu; Neil French; Cedric Mahe; David Yirrell; Christine Watera; Fred Lyagoba; Jessica Nakiyingi; Alleluiah Rutebemberwa; Dilys Morgan; Jonathan Weber; Charles Gilks; Jimmy Whitworth
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

4.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

5.  HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

Authors:  Jared M Baeten; Bhavna Chohan; Ludo Lavreys; Vrasha Chohan; R Scott McClelland; Laura Certain; Kishorchandra Mandaliya; Walter Jaoko; Julie Overbaugh
Journal:  J Infect Dis       Date:  2007-03-02       Impact factor: 5.226

6.  Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes.

Authors:  Joshua T Herbeck; Morgane Rolland; Yi Liu; Sherry McLaughlin; John McNevin; Hong Zhao; Kim Wong; Julia N Stoddard; Dana Raugi; Stephanie Sorensen; Indira Genowati; Brian Birditt; Angela McKay; Kurt Diem; Brandon S Maust; Wenjie Deng; Ann C Collier; Joanne D Stekler; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

7.  HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.

Authors:  Feng Yun Yue; Jared C Cohen; Mu Ho; A K M Nur-Ur Rahman; Jun Liu; Shariq Mujib; Aamir Saiyed; Sabrina Hundal; Alexandra Khozin; Phil Bonner; Daheng Liu; Erika Benko; Colin Kovacs; Mario Ostrowski
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

8.  Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.

Authors:  Ashwin Vasan; Boris Renjifo; Ellen Hertzmark; Beth Chaplin; Gernard Msamanga; Max Essex; Wafaie Fawzi; David Hunter
Journal:  Clin Infect Dis       Date:  2006-02-09       Impact factor: 9.079

Review 9.  Progress in achieving long-term HIV remission.

Authors:  Maria Pino; Mirko Paiardini; Vincent C Marconi
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

Review 2.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

3.  Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.

Authors:  Lori A Emert-Sedlak; Omar Moukha-Chafiq; Haibin Shi; Shoucheng Du; John J Alvarado; Vibha Pathak; Samuel G Tanner; Robert N Hunter; Miranda Nebane; Li Chen; Tatiana V Ilina; Rieko Ishima; Sixue Zhang; Yury V Kuzmichev; Elizabeth R Wonderlich; Susan M Schader; Corinne E Augelli-Szafran; Roger G Ptak; Thomas E Smithgall
Journal:  ACS Infect Dis       Date:  2022-01-05       Impact factor: 5.578

Review 4.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

Review 5.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

6.  Sulfated polymannuroguluronate TGC161 ameliorates leukopenia by inhibiting CD4+ T cell apoptosis.

Authors:  Chuanqin Shi; Wenwei Han; Meifang Zhang; Ruochen Zang; Kaixin Du; Li Li; Ximing Xu; Chunxia Li; Shixin Wang; Peiju Qiu; Huashi Guan; Jinbo Yang; Shuai Xiao; Xin Wang
Journal:  Carbohydr Polym       Date:  2020-07-06       Impact factor: 9.381

7.  Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.

Authors:  Marilia Rita Pinzone; D Jake VanBelzen; Sam Weissman; Maria Paola Bertuccio; LaMont Cannon; Emmanuele Venanzi-Rullo; Stephen Migueles; R Brad Jones; Talia Mota; Sarah B Joseph; Kevin Groen; Alexander O Pasternak; Wei-Ting Hwang; Brad Sherman; Anastasios Vourekas; Giuseppe Nunnari; Una O'Doherty
Journal:  Nat Commun       Date:  2019-02-13       Impact factor: 14.919

8.  Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study.

Authors:  Hanwei Sudderuddin; Natalie N Kinloch; Steven W Jin; Rachel L Miller; Bradley R Jones; Chanson J Brumme; Jeffrey B Joy; Mark A Brockman; Zabrina L Brumme
Journal:  Retrovirology       Date:  2020-01-09       Impact factor: 4.602

Review 9.  HIV-1 Latency and Latency Reversal: Does Subtype Matter?

Authors:  Indra Sarabia; Alberto Bosque
Journal:  Viruses       Date:  2019-11-28       Impact factor: 5.048

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.